Home Cart Sign in  
Chemical Structure| 1421438-81-4 Chemical Structure| 1421438-81-4

Structure of Crenigacestat
CAS No.: 1421438-81-4

Chemical Structure| 1421438-81-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY3039478 is a novel, potent Notch inhibitor with an IC50 of 0.41 nM.

Synonyms: LY3039478

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Crenigacestat

CAS No. :1421438-81-4
Formula : C22H23F3N4O4
M.W : 464.44
SMILES Code : O=C(N[C@@H](C)C(N[C@H]1C2=CC=CC=C2C3=CC=CN=C3N(CCO)C1=O)=O)CCC(F)(F)F
Synonyms :
LY3039478
MDL No. :MFCD26142650
InChI Key :YCBAQKQAINQRFW-UGSOOPFHSA-N
Pubchem ID :71236992

Safety of Crenigacestat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
KKU-M213 and KKU-M156 hetero-spheroids 5 µM 96 h Crenigacestat significantly reduced KKU-M213 and KKU-M156 hetero-spheroids viability compared to vehicle. PMC11484308
Cardiac Fibroblasts 10 μM 18 hours Inhibit Notch1 signaling pathway, counteract the protective effect of FSTL1 on cardiac fibroblasts PMC8695978
human primary CAFs 1-5-10 μM Crenigacestat significantly inhibited the intracellular domain of Notch1 (NICD1) and downregulated the HES1 gene at both mRNA and protein levels, indicating that CAFs are also a target of Crenigacestat. PMC9703776
MM.1S cells 10 nM 72 hours Crenigacestat alone and in combination with ATRA enhanced BCMA expression, with the combination showing the strongest effect. PMC9890012
OPM-2 cells 10 nM 72 hours Crenigacestat alone and in combination with ATRA enhanced BCMA expression, with the combination showing the strongest effect. PMC9890012

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CD1 nude mice xenograft model Oral gavage 8 mg/kg every 2 days for 20 days Crenigacestat treatment significantly decreased the tumor volume and fibrotic reaction. PMC11484308
CD-1 Nude mice HuCCT1-xenograft model Oral (gavage) 8 mg/kg 3 times/week for 4 weeks Crenigacestat significantly inhibited NOTCH1 and HES1, but did not affect tumor growth. Additionally, the drug triggered a strong immune response and blocked neovascularization in the tumor ecosystem of the HuCCT1-xenograft model without affecting the occurrence of fibrotic reactions. PMC9032805
Mice PDX model and hydrodynamic model Orally 8 mg/kg every two days for 3 weeks Crenigacestat significantly reduced peritumoral liver fibrosis in both PDX and hydrodynamic models and inhibited the TGF-β1 pathway and CAF activation. PMC9703776
CD-1 Nude mice iCCA xenograft model Oral gavage 8 mg/kg every 2 days for 35 days Crenigacestat significantly inhibited the growth of KKU-M213 and HuCCT1 xenograft tumors expressing high levels of CD90, indicating that Crenigacestat has therapeutic effects on CD90-positive tumors. PMC8851853
NSG mice MM.1S xenograft model Intraperitoneal injection 1 mg/kg Once daily for 12 days Combination treatment with ATRA and crenigacestat significantly enhanced the anti-myeloma efficacy of BCMA-CAR T cells and prolonged remission. PMC9890012

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02917733 Healthy PHASE1 COMPLETED 2025-11-16 Covance Clinical Research Inc,... More >> Madison, Wisconsin, 53704, United States Less <<
NCT02836600 Advanced Solid Tumor PHASE1 COMPLETED 2023-05-30 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Chiba, 277 8577, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.22mL

10.77mL

2.15mL

1.08mL

21.53mL

4.31mL

2.15mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories